Year |
Citation |
Score |
2024 |
Rosenthal MR, Vijayrajratnam S, Firestone TM, Ng CL. Enhanced cell stress response and protein degradation capacity underlie artemisinin resistance in . Msphere. 9: e0037124. PMID 39436072 DOI: 10.1128/msphere.00371-24 |
0.386 |
|
2023 |
Imhoff RD, Rosenthal MR, Ashraf K, Bhanot P, Ng CL, Flaherty DP. Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy. Bioorganic & Medicinal Chemistry Letters. 94: 129458. PMID 37634761 DOI: 10.1016/j.bmcl.2023.129458 |
0.318 |
|
2023 |
Rosenthal M, Ng C. Parasite proteostasis and artemisinin resistance. Research Square. PMID 37292709 DOI: 10.21203/rs.3.rs-2926003/v1 |
0.35 |
|
2023 |
Deni I, Stokes BH, Ward KE, Fairhurst KJ, Pasaje CFA, Yeo T, Akbar S, Park H, Muir R, Bick DS, Zhan W, Zhang H, Liu YJ, Ng CL, Kirkman LA, et al. Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome. Cell Chemical Biology. PMID 36963402 DOI: 10.1016/j.chembiol.2023.03.002 |
0.317 |
|
2021 |
Rosenthal MR, Ng CL. A Proteasome Mutation Sensitizes Cam3.II K13 Parasites to DHA and OZ439. Acs Infectious Diseases. PMID 33971094 DOI: 10.1021/acsinfecdis.0c00900 |
0.319 |
|
2020 |
Rosenthal MR, Ng CL. artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response. Acs Infectious Diseases. PMID 32324369 DOI: 10.1021/acsinfecdis.9b00527 |
0.333 |
|
2019 |
Stokes BH, Yoo E, Murithi JM, Luth MR, Afanasyev P, da Fonseca PCA, Winzeler EA, Ng CL, Bogyo M, Fidock DA. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. Plos Pathogens. 15: e1007722. PMID 31170268 DOI: 10.1371/Journal.Ppat.1007722 |
0.4 |
|
2018 |
White J, Dhingra S, Deng X, El Mazouni F, Lee M, Afanador G, Lawong A, Tomchick DR, Ng CL, Bath J, Rathod PK, Fidock DA, Phillips MA. Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265. Acs Infectious Diseases. PMID 30375858 DOI: 10.1021/Acsinfecdis.8B00211 |
0.368 |
|
2018 |
Yoo E, Stokes BH, de Jong H, Vanaerschot M, Kumar T, Lawrence N, Njoroge M, Garcia A, van der Westhuyzen R, Momper JD, Ng CL, Fidock DA, Bogyo M. Defining the determinants of specificity of Plasmodium proteasome inhibitors. Journal of the American Chemical Society. PMID 30107725 DOI: 10.1021/Jacs.8B06656 |
0.306 |
|
2018 |
Llanos-Cuentas A, Casapia M, Chuquiyauri R, Hinojosa JC, Kerr N, Rosario M, Toovey S, Arch RH, Phillips MA, Rozenberg FD, Bath J, Ng CL, Cowell AN, Winzeler EA, Fidock DA, et al. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. The Lancet. Infectious Diseases. PMID 29909069 DOI: 10.1016/S1473-3099(18)30309-8 |
0.337 |
|
2017 |
Vanaerschot M, Lucantoni L, Li T, Combrinck JM, Ruecker A, Kumar TRS, Rubiano K, Ferreira PE, Siciliano G, Gulati S, Henrich PP, Ng CL, Murithi JM, Corey VC, Duffy S, et al. Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. Nature Microbiology. PMID 28808258 DOI: 10.1038/S41564-017-0007-4 |
0.423 |
|
2017 |
Ng CL, Fidock DA, Bogyo M. Protein Degradation Systems as Antimalarial Therapeutic Targets. Trends in Parasitology. PMID 28688800 DOI: 10.1016/J.Pt.2017.05.009 |
0.458 |
|
2017 |
Sonoiki E, Ng CL, Lee MC, Guo D, Zhang YK, Zhou Y, Alley MR, Ahyong V, Sanz LM, Lafuente-Monasterio MJ, Dong C, Schupp PG, Gut J, Legac J, Cooper RA, et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nature Communications. 8: 14574. PMID 28262680 DOI: 10.1038/Ncomms14574 |
0.358 |
|
2016 |
Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, ... ... Ng CL, et al. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. Plos Medicine. 13: e1002138. PMID 27701420 DOI: 10.1371/Journal.Pmed.1002138 |
0.318 |
|
2016 |
Ng CL, Siciliano G, Lee MC, de Almeida MJ, Corey VC, Bopp SE, Bertuccini L, Wittlin S, Kasdin RG, Le Bihan A, Clozel M, Winzeler EA, Alano P, Fidock DA. CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs. Molecular Microbiology. PMID 27073104 DOI: 10.1111/Mmi.13397 |
0.4 |
|
2015 |
Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, ... Ng CL, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Science Translational Medicine. 7: 296ra111. PMID 26180101 DOI: 10.1126/Scitranslmed.Aaa6645 |
0.357 |
|
2013 |
Brunner R, Ng CL, Aissaoui H, Akabas MH, Boss C, Brun R, Callaghan PS, Corminboeuf O, Fidock DA, Frame IJ, Heidmann B, Le Bihan A, Jenö P, Mattheis C, Moes S, et al. UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells. The Journal of Biological Chemistry. 288: 22576-83. PMID 23754276 DOI: 10.1074/Jbc.M113.453159 |
0.417 |
|
2012 |
Ng CL, Fidock DA. No evidence of decreased artemisinin efficacy in a high-transmission malaria setting in Mali. The American Journal of Tropical Medicine and Hygiene. 87: 16-7. PMID 22764285 DOI: 10.4269/Ajtmh.2012.12-0344 |
0.396 |
|
2010 |
Ng CL, Oresic K, Tortorella D. TRAM1 is involved in disposal of ER membrane degradation substrates. Experimental Cell Research. 316: 2113-22. PMID 20430023 DOI: 10.1016/J.Yexcr.2010.04.010 |
0.525 |
|
2009 |
Oresic K, Ng CL, Tortorella D. TRAM1 participates in human cytomegalovirus US2- and US11-mediated dislocation of an endoplasmic reticulum membrane glycoprotein. The Journal of Biological Chemistry. 284: 5905-14. PMID 19121997 DOI: 10.1074/Jbc.M807568200 |
0.524 |
|
2003 |
Safferling M, Griffith H, Jin J, Sharp J, De Jesus M, Ng C, Krulwich TA, Wang DN. TetL tetracycline efflux protein from Bacillus subtilis is a dimer in the membrane and in detergent solution. Biochemistry. 42: 13969-76. PMID 14636065 DOI: 10.1021/Bi035173Q |
0.367 |
|
Show low-probability matches. |